Athira Pharma (NASDAQ:LONA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Athira Pharma (NASDAQ:LONA) to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings assumed coverage on shares of Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Athira Pharma currently has an average rating of “Sell”.

Athira Pharma Stock Performance

LONA stock opened at $4.34 on Friday. Athira Pharma has a 12 month low of $2.20 and a 12 month high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.